Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia. or B, with and without Inhibitors: An Integrated Analysis of Safety

被引：0
|
作者：
Acharya, Suchitra [1 ]
Matino, Davide [2 ]
Mahlangu, Johnny [3 ,4 ]
Turich, Carrie [5 ]
Hwang, Eunhee [6 ]
Hinnershitz, Tina [7 ]
Mefyod, Eugeny [8 ]
Palladino, Andrew [6 ]
Biondo, Francesca [7 ]
Gould, Travis [5 ]
Teeter, John [7 ]
机构：
[1] Cohen Childrens Med Ctr New York, New Hyde Pk, NY USA
[2] Thrombosis & Atherosclerosis Res Inst TaARI, Hamilton, ON, Canada
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Natl Hlth Lab Serv, Johannesburg, South Africa
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer Inc, Groton, CT USA
[8] Pfizer Inc, Smolensk, Russia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174682
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 45 条
  • [31] An Antibody to Tissue Factor Pathway Inhibitor (PF-06741086) in Combination with Recombinant Factor VIIa Increases Hemostasis in Hemophilia Plasma without Excessive Thrombin Generation
    Rakhe, Swapnil
    Hett, Sunita Patel
    Murphy, John E.
    Pittman, Debra D.
    BLOOD, 2016, 128 (22)
  • [32] Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis
    Mancuso, Maria Elisa
    Ingham, Sheila J. M.
    Kunze, Marc
    HAEMOPHILIA, 2022, 28 (05) : 702 - 712
  • [33] Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay
    Waters, E. K.
    Sigh, J.
    Friedrich, U.
    Hilden, I.
    Sorensen, B. B.
    HAEMOPHILIA, 2017, 23 (05) : 769 - 776
  • [34] Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment
    Chrisentery-Singleton, Tammuella
    Alexander, W. Allan
    Al-Sabbagh, Ahmad
    Bonzo, Daniel
    Callaghan, Michael U.
    Escobar, Miguel A.
    Giermasz, Adam
    Hirsh, Nikki
    Journeycake, Janna
    Nar, Sonia
    Quon, Doris V.
    Recht, Micael
    BLOOD, 2021, 138
  • [35] ATHN 16: SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW FOR THE TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS WITH OR WITHOUT PROPHYLACTIC TREATMENT
    Chrisentery-Singleton, T.
    Alexander, W. A.
    Al-Sabbagh, A.
    Escobar, M.
    Giermasz, A.
    Journeycake, J.
    Nasr, S.
    Quon, D.
    Recht, M.
    Bonzo, D.
    Hirsh, N.
    Reding, M.
    Callaghan, M.
    HAEMOPHILIA, 2022, 28 : 40 - 41
  • [36] ATHN 16: SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW FOR THE TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS WITH OR WITHOUT PROPHYLACTIC TREATMENT
    Chrisentery-Singleton, Tammuella
    Alexander, W. Allan
    Al-Sabbagh, Ahmad
    Bonzo, Daniel
    Callaghan, Michael U.
    Escobar, Miguel
    Giermasz, Adam
    Hirsh, M. Nikki
    Journeycake, Janna
    Nasr, Sonia
    Quon, Doris V.
    Reding, Mark
    Recht, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E20 - E21
  • [37] Mutational analysis of pig tissue factor pathway inhibitor α to increase anti-coagulation activity in pig-to-human xenotransplantation
    Lee, Chang-Hee
    Lee, Hyeon Jeong
    Park, Si-Won
    Shin, Jiyoon
    Kang, Seok-Jin
    Park, In-Byung
    Kim, Hyun Kyung
    Chun, Taehoon
    BIOTECHNOLOGY LETTERS, 2024, 46 (04) : 521 - 530
  • [38] A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors
    Chrisentery-Singleton, Tammuella
    Amos, Lauren E.
    Bonzo, Daniel
    Escobar, Miguel
    Giermasz, Adam
    Lagrue, Emmanuelle
    Knoll, Christine
    Nasr, Sonia
    Recht, Michael
    Sullivan, Spencer
    Quon, Doris, V
    Reding, Mark T.
    BLOOD, 2022, 140 : 11360 - 11361
  • [39] A Neutralizing Monoclonal Antibody (PF06741086) Against Tissue Factor Pathway Inhibitor in Combination with Activated Prothrombin Complex Concentrate Increases Hemostasis in Inhibitor Hemophilia Plasmas without Excessive Thrombin Generation
    Rakhe, Swapnil
    Bowley, Sheryl
    Murphy, John E.
    Pittman, Debra D.
    BLOOD, 2018, 132
  • [40] A monoclonal antibody mAB 2021 blocks tissue factor pathway inhibitor (TFPI) and enhances hemostasis in whole blood under hemophilia A- and B- like conditions equally well
    Sorensen, B.
    Petersen, L.
    Hilden, I.
    HAEMOPHILIA, 2012, 18 : 141 - 141
12345